Global Institute Of Stem Cell Therapy And Research

Category

News

GIOSTAR: Worldwide Network of Stem Cell Hospital and Research Centers

(ED NOTE: There is no other area of Healthcare that sorely need both healthcare worker education, and patient education, than the field of Stem Cells; there seems to be an unlimited source of promise, and an area that needs continuing research to mine this tremendous promise.  This entire post is taken from the website of this organization.  The San Diego office is a Research Center)

Global Institute of Stem Cell Therapy and Research (GIOSTAR), headquartered in San Diego, California (U.S.A.), was formed with the vision to provide stem cell based therapy to aid those suffering from degenerative or genetic diseases around the world.

We are the leaders in developing cutting edge stem cell based technology, supported by leading scientists with the pioneering publications in the area of stem cell biology. Our primary focus is to discover and develop a cure for human diseases with innovative and unique stem cell based therapies and products. Regenerative medicine promises treatment for those diseases previously regarded as incurable. GIOSTAR’s ultimate aim is to maintain its leadership in the field of stem cell science and to continue developing affordable stem cell based therapy for those in need.

In July 2011, GIOSTAR inaugurated the world’s first dedicated stem cell treatment hospital at Ahmedabad, Gujarat, India. This is a 125-bed state of the art facility with the most advanced on-site stem cell laboratory.

GIOSTAR has an ability to treat several devastating Immunological diseases and Blood related diseases. These include Diabetes Type I, Lupus, Multiple Sclerosis, Crohns, Vasculitis, Scleroderma, Myasthenia Gravis, Sickle cell anemia, Leukemia, Lymphoma, Thalassemia and developing the therapies for Alzheimer’s, Autism, Anti-Aging Treatments, Parkinson’s, , Cancer, Heart and Retinal Degeneration, Amyyotrophic Lateral Sclerosis, Neuropathy, Osteoarthritis, Paralysis, Strokes, Spinal Cord Injuries, Skin Burns and Spinal Muscular Atrophy (SMA).

GIOSTAR is in process of opening dedicated stem cell treatment hospitals in Asia, Middle East, Africa, North and South America and Europe. The proposed facilities will be developed with the international support from public and private sectors grants and investments to provide stem cell based therapy for those suffering from degenerative or genetic diseases.

GIOSTAR uses autologous and allogeneic adult stem cells transplant to treat patients, following the highest medical standards.

GIOSTAR is leading the most advanced research to use embryonic stem (ES) cells and Induced Pluripotent Stem (IPS) cells to develop new therapies for clinical use.

GIOSTAR is a coalition of esteemed and illustrious scientific minds in the field of genetic and stem cell science. For over 15 years GIOSTAR team of scientists and clinicians have been involved in the development and utilization of stem cell based clinical protocols related to stem cell transplants.

The GIOSTAR team includes international leaders in the field of embryonic stem (ES) cells and Induced Pluripotent Stem (IPS) cells research and technologies. GIOSTAR team is the first in demonstrating the significance of ES cell use for the development of therapies for several degenerative diseases related to tissue and organs. The publications of these therapies have been thoroughly investigated and documented by many noted journals of medicine. GIOSTAR cutting-edge Stem Cell science will be used to treat qualified patients on needed basis.

GIOSTAR is using three kinds of stem cells : adult stem cell, human embryonic stem cell and Induced Pluripotent cells. The adult stem cell technology is well developed and being used regularly in clinical practice. Our clinicians are licensed to treat the patients using autologous (their own) and allogeneic (from others) adult stem cells for certain diseases. We are the leading private organization, which has state of art excellence in extraction of stem cell from a human body and use it for therapy. Our clinicians are treating the patients regularly using adult stem cells since 2000. GIOSTAR is leading the most advanced research to use embryonic stem (ES) cells and Induced Pluripotent Stem (IPS) cells to develop new therapies for clinical use.

Global Institute of Stem Cell Therapy and Research (GIOSTAR) Chairman Dr. Anand Srivastava and CEO Mr. Deven Patel were among the invited guests at the San Diego Regional Chamber of Commence hosted Congressional Luncheon on April 19, 2013. This is one of San Diego’s best opportunities to hear directly from the San Diego regional congressional delegation and to exchange the ideas with leadership.

Among the congressional attendees, Congresswoman Susan Davis, Congressman Duncan D. Hunter, Congressman Darrell Issa, Congressman Scott Peters, Congressman Juan Vargas were present at the luncheon.

GIOSTAR Chairman Dr. Anand Srivastava had a long talk with Congressman Scott Peters regarding visa problem faced by the Professionals in the scientific communities in San Diego area.  These highly qualified scientists immigrating from India, China and other parts of the world are not getting their conclusive immigrant status after working for seven to ten years at the local institutions and contributing great deal in the advancement of scientific research.

Congressional Luncheon 1 Congressional Luncheon 2 Congressional Luncheon 3 Congressional Luncheon 4

Congresswoman Susan Davis and GIOSTAR CEO Mr. Deven Patel discussed small business grants in the biotechnology field and finding a ways to boost local biotech business.  “San Diego being very strong incubator for biotech research, it can not affords to loose its ground due to lack of funding,” said Mr. Patel.

Today GIOSTAR scientists study all three types of stem cells: tissue-derived stem cells, embryonic stem (ES) cells and induced pluripotent stem (iPS) cells, as well as progenitor cells. Molecular biology, genetic engineering and protein chemistry are core technologies for conducting this research. We consider all of these cell types as viable options both as cell-based therapies and as tools and technologies for drug discovery and development.

Dr. Anand Srivastava said he had very fruitful conversation with Congressman Juan Vargas for developing entire Baha California region for biotech and research industry.

Congressman Vergas was very open to the idea for developing entire region and make San Diego the epicenter for all developments.

Global Institute of Stem Cell Therapy and Research (GIOSTAR) Chairman Dr. Anand Srivastava and CEO Mr. Deven Patel were among the invited guests at the San Diego Regional Chamber of Commence hosted Congressional Luncheon on April 19, 2013. This is one of San Diego’s best opportunities to hear directly from the San Diego regional congressional delegation and to exchange the ideas with leadership.

Among the congressional attendees, Congresswoman Susan Davis, Congressman Duncan D. Hunter, Congressman Darrell Issa, Congressman Scott Peters, Congressman Juan Vargas were present at the luncheon.

GIOSTAR Chairman Dr. Anand Srivastava had a long talk with Congressman Scott Peters regarding visa problem faced by the Professionals in the scientific communities in San Diego area.  These highly qualified scientists immigrating from India, China and other parts of the world are not getting their conclusive immigrant status after working for seven to ten years at the local institutions and contributing great deal in the advancement of scientific research.

Congresswoman Susan Davis and GIOSTAR CEO Mr. Deven Patel discussed small business grants in the biotechnology field and finding a ways to boost local biotech business.  “San Diego being very strong incubator for biotech research, it can not affords to loose its ground due to lack of funding,” said Mr. Patel.

Today GIOSTAR scientists study all three types of stem cells: tissue-derived stem cells, embryonic stem (ES) cells and induced pluripotent stem (iPS) cells, as well as progenitor cells. Molecular biology, genetic engineering and protein chemistry are core technologies for conducting this research. We consider all of these cell types as viable options both as cell-based therapies and as tools and technologies for drug discovery and development.

Dr. Anand Srivastava said he had very fruitful conversation with Congressman Juan Vargas for developing entire Baha California region for biotech and research industry.

Congressman Vergas was very open to the idea for developing entire region and make San Diego the epicenter for all developments.

GIOSTAR Executives Invited to Congressional Luncheon Giostar2 Giostar3 Giostar4

GIOSTAR and the Government of India to Enter $2 Billion Stem Cell Therapy Program - Official State Visit by Chief Minister to San Diego Headquarters

The Global Institute Of Stem-cell Therapy And Research (GIOSTAR) announced today a collaborative treatment plan to serve the local population suffering from a genetic disease, Sickle Cell Anemia. President and CEO, Mr. Deven Patel and his team met with Honorable Chief Minister Shri Arjun Munda of State of Jharkhand, India in November 2012 to address the local population’s medical needs.

As a follow-up, a government delegation representing the state of Jharkhand, India; Chief Minister, Principal Health Secretary, Chief Secretary and many other officials are visiting GIOSTAR in San Diego on December 14, 2012 to finalize the proposed two (2) billion U.S. dollar contract to be serviced over the next 15 years.

Bob Filner, Mayor of San Diego and City Council Members are among the invited guests for this state visit along with representatives from Belize and the island nation of Saint Vincent and the Grenadines.

Two hundred (200) jobs are estimated to be created in San Diego and it is expected that the dialog would include an economic development program between City of San
Diego and State of Jharkhand, India.

GIOSTAR is a Global Private Funding (Global) incubated company. “Global is a private equity firm that focuses on funding projects and initiatives that are jobcreation centric rather than just profit centric. We believe that a venture that draws the best minds and hearts to a unified goal, driven by a unified vision tends to be far stronger and less prone to failure than one driven by just profit. We invest in people, not the business,” said Dr. Sam Senev, Chairman and CEO of Global. Senev added that GIOSTAR is a showcase client focused on both serving mankind through quality of life and job creation.

GIOSTAR, headquartered in San Diego, California (USA), was formed with the vision to provide stem cell based therapy to aid those suffering from degenerative or genetic diseases around the world. We are the leaders in developing innovative stem cell based technology.

The Chairman and Cofounder of GIOSTAR, Dr. Anand Srivastava and our team of scientists and clinicians have been associated with leading universities and research institutions throughout USA. GIOSTAR team has extensive research and clinical experience in the field of Stem cell, which is documented by several publications in
revered scientific journals.

GIOSTAR in July 2011, inaugurated the world’s first dedicated stem cell treatment hospital, a 125-bed, contemporary facility with the most advanced on-site stem cell laboratory.

This hospital is fully operational. GIOSTAR is developing the world’s largest, a three hundred thousand square-foot (300,000SF) state-of-the-art, Stem Cell Treatment Hospital in the Surat Civil Hospital Campus in collaboration with the government of Gujarat. Negotiations are ongoing with China, Philippines, Bahamas, Belize, Thailand, Ukraine and the Middle East to open regional stem cell treatment hospitals and satellite clinics throughout those countries and regions.

“We are expanding the GIOSTAR footprint and is in negotiations to open locations near Austin Texas, Phoenix Arizona, and Savannah South Carolina” said Michael Andersen, Vice President of Venture Management at Global. Global and Empyrean West, EB-5 administrators, plan to invest over one hundred and eighty million ($180M) in economic development investments for GIOSTAR projects.

CONTACT: Deven Patel
Chairman & CEO
Global Institute Of Stem-cell Therapy and Research (GIOSTAR)

858-618-4741
Deven@Giostar.com
www.Giostar.com

Mary Kananen
Program Director, Community Outreach
Global Private Funding Inc.

800-226-8146 | 805-807-2943
MaryKananen@GlobalPrivateFunding.com
www.GlobalPrivateFunding.com

Nasdaq News GIOSTAR

SAN DIEGO, Dec. 10, 2012 (GLOBE NEWSWIRE) — The Global Institute Of Stem-cell Therapy And Research (GIOSTAR) announced today a collaborative treatment plan to serve the local population suffering from a genetic disease, Sickle Cell Anemia. President and CEO, Mr. Deven Patel and his team met with Honorable Chief Minister Shri Arjun Munda of State of Jharkhand, India in November 2012 to address the local population’s medical needs.

GIOSTAR and the Government of India to Enter $2 Billion Stem Cell Therapy Program

A photo accompanying this release is available at http://www.globenewswire.com/newsroom/prs/?pkgid=16184.

As a follow-up, a government delegation representing the state of Jharkhand, India; Chief Minister, Principal Health Secretary, Chief Secretary and many other officials are visiting GIOSTAR in San Diego on December 14, 2012 to finalize the proposed two (2) billion U.S. dollar contract to be serviced over the next 15 years.

Bob Filner, Mayor of San Diego and City Council Members are among the invited guests for this state visit along with representatives from Belize and the island nation of Saint Vincent and the Grenadines.

Two hundred (200) jobs are estimated to be created in San Diego and it is expected that the dialog would include an economic development program between City of San Diego and State of Jharkhand, India.

GIOSTAR is a Global Private Funding (Global) incubated company. “Global is a private equity firm that focuses on funding projects and initiatives that are job-creation centric rather than just profit centric. We believe that a venture that draws the best minds and hearts to a unified goal, driven by a unified vision tends to be far stronger and less prone to failure than one driven by just profit. We invest in people, not the business,” said Dr. Sam Senev, Chairman and CEO of Global. Senev added that GIOSTAR is a showcase client focused on both serving mankind through quality of life and job creation.

GIOSTAR, headquartered in San Diego, California (USA), was formed with the vision to provide stem cell based therapy to aid those suffering from degenerative or genetic diseases around the world. We are the leaders in developing innovative stem cell based technology.

The Chairman and Cofounder of GIOSTAR, Dr. Anand Srivastava and our team of scientists and clinicians have been associated with leading universities and research institutions throughout USA. GIOSTAR team has extensive research and clinical experience in the field of Stem cell, which is documented by several publications in revered scientific journals.

GIOSTAR in July 2011, inaugurated the world’s first dedicated stem cell treatment hospital, a 125-bed, contemporary facility with the most advanced on-site stem cell laboratory. This hospital is fully operational. GIOSTAR is developing the world’s largest, a three hundred thousand square-foot (300,000SF) state-of-the-art, Stem Cell Treatment Hospital in the Surat Civil Hospital Campus in collaboration with the government of Gujarat. Negotiations are ongoing with China, Philippines, Bahamas, Belize, Thailand, Ukraine and the Middle East to open regional stem cell treatment hospitals and satellite clinics throughout those countries and regions. “We are expanding the GIOSTAR footprint and is in negotiations to open locations near Austin Texas, Phoenix Arizona, and Savannah South Carolina” said Michael Andersen, Vice President of Venture Management at Global. Global and Empyrean West, EB-5 administrators, plan to invest over one hundred and eighty million ($180M) in economic development investments for GIOSTAR projects.

The Global Institute of Stem Cell Therapy and Research company logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=16183.

Deven Patel
Chairman & CEO
Global Institute Of Stem-cell Therapy and Research (GIOSTAR)
858-618-4741

www.Giostar.com

Mary Kananen
Program Director, Community Outreach
Global Private Funding Inc.
800-226-8146 | 805-807-2943

www.GlobalPrivateFunding.com

Make An Enquiry

We are here to help you

WordPress Video Lightbox